Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W M Johnson

Showing results (191-200 of 218) with videos related to

Pageof 22
Sort By:
Blood Advances|August 18, 2023
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCLJohn R Davies, Laura K Hilton, Aixiang Jiang, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
The American Journal of Pathology|January 1, 2003
Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulinsStefano A Pileri, Gianluca Gaidano, Pier Luigi Zinzani, et al.
Blood|June 20, 2015
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphomaLuca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Blood|March 13, 2010
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionStephen A Beers, Ruth R French, H T Claude Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic LeukemiaMatthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Blood|May 10, 2015
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse modelMatthew D Blunt, Matthew J Carter, Marta Larrayoz, et al.
BMJ (Clinical Research Ed.)|September 18, 2021
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort studyJulia Hippisley-Cox, Carol Ac Coupland, Nisha Mehta, et al.
Blood|July 20, 2011
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacySean H Lim, Andrew T Vaughan, Margaret Ashton-Key, et al.
Pageof 22

Showing results (191-200 of 218) with videos related to

Sort By:
Pageof 22
Blood Advances|August 18, 2023
Comparison of MHG and DZsig reveals shared biology and a core overlap group with inferior prognosis in DLBCLJohn R Davies, Laura K Hilton, Aixiang Jiang, et al.
British Journal of Haematology|August 2, 2016
Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) in the management of primary mediastinal B-cell lymphoma: a subgroup analysis of the UK NCRI R-CHOP 14 versus 21 trialMary Gleeson, Eliza A Hawkes, David Cunningham, et al.
The American Journal of Pathology|January 1, 2003
Primary mediastinal B-cell lymphoma: high frequency of BCL-6 mutations and consistent expression of the transcription factors OCT-2, BOB.1, and PU.1 in the absence of immunoglobulinsStefano A Pileri, Gianluca Gaidano, Pier Luigi Zinzani, et al.
Blood|June 20, 2015
Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphomaLuca Ceriani, Maurizio Martelli, Pier Luigi Zinzani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 7, 2014
[18F]fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 StudyMaurizio Martelli, Luca Ceriani, Emanuele Zucca, et al.
Blood|March 13, 2010
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionStephen A Beers, Ruth R French, H T Claude Chan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 5, 2016
The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic LeukemiaMatthew D Blunt, Stefan Koehrer, Rachel C Dobson, et al.
Blood|May 10, 2015
The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse modelMatthew D Blunt, Matthew J Carter, Marta Larrayoz, et al.
BMJ (Clinical Research Ed.)|September 18, 2021
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort studyJulia Hippisley-Cox, Carol Ac Coupland, Nisha Mehta, et al.
Blood|July 20, 2011
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacySean H Lim, Andrew T Vaughan, Margaret Ashton-Key, et al.
Pageof 22